Sign in

AXIS Capital Holdings Limited AXS

Price 99.7 USD
as of 2026-09-03
58/100
Constructive
Quality56
Growth41
Balance-sheet strength50
Valuation88
Momentum45
Income55

Composite 58/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Growth ranks 41/100 — a slight mark against it.

Case for

Valuation ranks 88/100 — a strong point in its favour. Quality ranks 56/100 — a slight point in its favour. Income ranks 55/100 — a slight point in its favour.

Case against

Growth ranks 41/100 — a slight mark against it. Momentum ranks 45/100 — a slight mark against it.

What the company does AXIS Capital Holdings (AXS) underwrites specialty insurance and reinsurance across property, marine, aviation, and professional lines, serving commercial enterprises and financial institutions globally.

Key financials AXS posts ROE 17% and ROA 3%, with gross/operating/net margins of 32%/19%/16%. Revenue grew 8% and EPS 46%, while debt/equity is 0.23 and interest coverage 20x. Dividend yield is 1.5% with a 13% payout ratio.

Stock health Momentum shows 14% over 12m but -12% from the 52w high; RSI(14) is 42. Sideravia scores Valuation 89/100 but Quality 50/100, indicating average fundamentals despite attractive pricing.

Price vs fair value The stock trades at a discount to both our fair-value estimate and analyst target. - AXS is down 70% below our fair-value estimate of 180.41 (Our fair-value estimate). - AXS is down 19% below the 12-month target of 126.27 (analyst count 11). - Q2 2026 earnings missed estimates on higher catastrophe losses (Zacks). - Adjusted EPS fell below analyst expectations in Q2 (StockStory). - Simply Wall St asks if AXS is a bargain as earnings approach (Simply Wall St).

Looking forward Forward P/E of 9x and FCF yield 30% suggest valuation support, but weak Q2 results and below-target growth metrics temper near-term sentiment. Analysts remain cautious despite the steep discount.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.